| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2016-10-27 | maribavir | cytomegalovirus infections | 2 | Shire (UK - USA) | Infectious diseases |
| 2016-10-27 | QR-010 | cystic fibrosis | 1 | ProQR Therapeutics (The Netherlands) | Rare diseases - Genetic diseases - Lung diseases |
| 2016-10-27 | ALXN1210 (ravulizumab - Fc- and CDR-modified humanised monoclonal antibody against C5) | paroxysmal nocturnal hemoglobinuria (PNH) | 3 | Alexion Pharmaceuticals (USA - CT) | Rare diseases - Immunological diseases |
| 2016-10-27 | ALXN1210 (ravulizumab - Fc- and CDR-modified humanised monoclonal antibody against C5) | atypical hemolytic uremic syndrome (aHUS) | 3 | Alexion Pharmaceuticals (USA - CT) | Rare diseases - Kidney diseases - Renal diseases |
| 2016-10-27 | THN102 - combination of modafinil and flecainide | narcolepsy | 2 | Theranexus (France) | Rare diseases - Neurological diseases |
| 2016-10-27 | relamorelin (RM-131) | gastroparesis in patients with type 1 and type 2 diabetes | 2b | Actavis (Ireland) Rhythm, now Motus Therapeutics (USA - IL) | Gastrointestinal diseases - Metabolic diseases |
| 2016-10-26 | venetoclax (RG7601, GDC-0199/ABT-199) and ABBV-838 | multiple myeloma | 1 | Abbvie (USA - IL) | Cancer - Oncology |
| 2016-10-26 | F901318 (2-(1,5-dimethyl-3-phenyl-1H-pyrrol-2-yl)-N-{4-[4-(5-fluoro-pyrimidin-2-yl)piperazin-1-yl]- phenyl}-2-oxo-acetamide) | aspergillosis | preclinical | F2G (UK) | Infectious diseases |
| 2016-10-26 | Viaskin® Peanut | peanut allergy | 2 | Consortium for Food Allergy Research - CoFAR (USA) DBV Technologies (France) | Allergic diseases - Immunological diseases |
| 2016-10-26 | BI 695501 (biosimilar version of Humira® (adalimumab)) | rheumatoid arthritis | 3 | Boehringer Ingelheim (Germany) | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
| 2016-10-26 | ATX-GD-459 | Graves' disease | 1 | Apitope (UK - Belgium) | Autoimmune diseases |
| 2016-10-25 | apatorsen (OGX-427) | metastatic bladder cancer | 2 | OncoGenex Pharmaceuticals (USA - WA) | Cancer - Oncology |
| 2016-10-25 | PRX-102 (alpha-galactosidase-A) | Fabry disease | 3 | Protalix BioTherapeutics (Israel) | Rare diseases - Genetic diseases |
| 2016-10-24 | bavituximab and anti PD-L1 therapy | triple-negative breast cancer (TNBC) | preclinical | Peregrine Pharmaceuticals (USA - CA) | Cancer - Oncology |
| 2016-10-21 | pexidartinib (PLX3397) | tenosynovial giant cell tumour | 3 | Daiichi Sankyo (Japan) | Cancer - Oncology |
| 2016-10-21 | napabucasin (BBI608) | colorectal cancer | 3 | Boston Biomedical (USA - MA) | Cancer - Oncology |
| 2016-10-20 | ALKS 5461 | major depressive disorder (MDD) | 3 | Alkermes (Ireland) | CNS diseases - Mental diseases |
| 2016-10-20 | TGR-1202 and carfilzomib | relapsed and refractory non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL) | 1-2 | TG Therapeutics (USA - NY) | Cancer - Oncology |
| 2016-10-20 | selonsertib (GS-4997) | pulmonary arterial hypertension (PAH) | 2 | Gilead Sciences (USA - CA) | Rare diseases - Cardiovascular diseases |
| 2016-10-20 | selonsertib (GS-4997) | diabetic kidney disease | 2 | Gilead Sciences (USA - CA) | Kidney diseases - Metabolic diseases - Renal diseases |
